InMed Pharmaceuticals Inc. — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
InMed Pharmaceuticals completed a merger with Mentari Therapeutics on November 9, 2026. The combined entity raised $490 million gross in private placements led by Fairmount (including $50 million convertible note conversion), with participation from 17+ investment firms. Post-merger, ~58.3 million shares outstanding; company trades on Nasdaq under ticker MTRI with cash runway into 2029 to fund migraine drug pipeline (MT-001 Phase 1 data mid-2027; MT-002 regulatory filing Q1 2027, data end-2027).
Why this rating
Reverse merger into clinical-stage biotech with $490M funding is transformational for $3M InMed. Provides massive capital infusion (163× company market cap), public listing, and multi-year runway. High execution risk on pipeline, but capitalization change is business-altering.
Tradability signal
NO TRADE
No trade: positive news with no measurable pre-read move — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -2.37% over 4 hrs, n=22). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $15.56 | +10 min · unknown $15.56 ▲ 0.00% | +30 min · unknown $15.56 ▲ 0.00% | +1 hr · unknown $15.56 ▲ 0.00% | +4 hrs · unknown $15.56 ▲ 0.00% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.